Peng (Kate) G.
About Peng (Kate) G.
Peng (Kate) G. is the Director of Applied Innovation Content Strategy & Special Initiatives at BeiGene, with a background in neuroscience and molecular genetics. She has extensive experience in scientific content management and has worked in both the pharmaceutical and publishing sectors.
Title and Current Position
Peng (Kate) G. is currently the Director of Applied Innovation Content Strategy & Special Initiatives at BeiGene. In this role, she is responsible for driving innovation and managing special initiatives within the organization's content strategy frameworks.
Previous Roles at Eisai US
From 2020 to 2022, Peng (Kate) G. served as the Director of Strategic Scientific Content Management in the Global Medical Affairs division for the Neurology Business Group at Eisai US. This role was based in Woodcliff Lake, New Jersey. During her tenure, she led several strategic initiatives aimed at managing and enhancing scientific content in the field of neurology.
Experience at Nature Research
Peng (Kate) G. worked at Nature Research in various editorial roles. From 2017 to 2020, she was a Scientific Editor at Nature Medicine in the Greater New York City Area, working on high-impact scientific publications. Prior to that, she was a Scientific Editor at Nature Communications in New York from 2015 to 2017. Her work involved overseeing the publication of significant research articles and managing peer review processes.
Education and Academic Background
Peng (Kate) G. obtained a PhD in Neuroscience from Weill Cornell Medical College, completing her studies from 2010 to 2015. Before that, she was a PhD candidate in Molecular and Human Genetics at Baylor College of Medicine from 2008 to 2010. She also holds a Bachelor of Science (B.S.) in Biological and Biomedical Sciences from Nankai University, where she studied from 2004 to 2008.
Scientific Content and Strategic Initiatives
Throughout her career, Peng (Kate) G. has developed and managed scientific content strategies across various fields, including neurology. Her roles have involved leading strategic initiatives, managing high-impact scientific publications, and leveraging her extensive background in both neuroscience and molecular genetics to transition from academia to strategic roles in the pharmaceutical and publishing sectors.